Breaking News
Topical tacrolimus in the treatment of lichen sclerosus with genital and extragenital involvement
Topical tacrolimus in the treatment of lichen sclerosus with genital and extragenital involvement
A prospective, open study evaluated the efficacy and safety of topical tacrolimus 0.1% ointment in 16 patients with anogenital (n = 10) or extragenital (n = 6) lichen sclerosus. Patients were treated with tacrolimus twice daily until complete disappearance or stabilization of lesions. The effects were graded in three ways: complete response (75% or greater improvement); partial response (25-75% improvement); no response (25% or less improvement). A telephone survey assessed the long-term outcome and relapse rate. An objective response was seen in 90 and 16.7% of the anogenital and extragenital groups, respectively. In the anogenital group, 50% of the patients had a complete response. A partial response was seen in 40% ...
Last updated: Tuesday, November 29, 2011
AccessDermatology | © Copyright 2011 Prous Science S.A.U. a Thomson Reuters business or its licensors.
All rights reserved. Legal Information. Send your comments to Webmaster
ISSN 2013-8202
This website is optimized for Explorer 7.0 and above, Firefox 3.0, Safari, and Chrome. Content remains viewable in older versions, but loss of formatting and design elements may occur.
This site complies with the HONcode standard for trustworthy health information:
verify here.